NCT06801067RecruitingPhase 1
A Single-Arm, Open-Label, Phase 1 Study to Assess Safety and Preliminary Efficacy of Cultivated Multi-Strain Live Bacterial Therapeutic SER-155 for First-Line Treatment of Immunotherapy-Related Enterocolitis
Memorial Sloan Kettering Cancer Center7 sites in 1 country15 target enrollmentStarted: January 24, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 15
- Locations
- 7
- Primary Endpoint
- Proportion of patients with treatment-related adverse events
Study Overview
Brief Summary
The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age > 18 years
- •Receipt of ICI (single-agent or combination) within the 180 days preceding screening.
- •Concurrent treatment with cytotoxic chemotherapy or other tumor-directed agents is permitted.
- •Grade 2 - 3 diarrhea (i.e., increase of at least 4 bowel movements a day above baseline during the screening window), deemed by the treating provider as likely related to ICI therapy, with or without concomitant symptoms of grade 1 - 2 colitis (e.g.
- •abdominal pain, bloody or mucoid stools)
- •Able to swallow oral medication
- •Individuals of childbearing potential willing to use a highly effective method of contraception (failure rate of <1% per year when used consistently and correctly) for 30 days after the last dose of SER-
- •Willing to provide written informed consent, comply with the protocol, and understand the potential risks and benefits of study enrollment and treatment.
Exclusion Criteria
- •Active GI infection, including untreated viral, bacterial or fungal cause(s) of diarrhea.
- •Received immunosuppressive therapies for suspected or confirmed irEC, including systemic corticosteroids (either oral or intravenous) and/or infliximab, vedolizumab or ustekinumab
- •Grade 3 colitis symptoms, i.e. severe abdominal pain or peritoneal signs
- •Admitted to the hospital for irEC
- •Prednisone (or steroid equivalent) dose > 10 mg a day for a non-GI irAE at time of screening
- •Pre-existing inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) or microscopic colitis
- •Pregnant or lactating women
- •Any condition that requires ongoing prophylactic or therapeutic antibacterial antibiotics
- •Severe neutropenia, as defined by an absolute neutrophil count (ANC) < 500 cells/mm^3, at time of screening
- •Treatment with investigational medications used for diarrhea/colitis treatment and microbiome therapeutics within 30 days prior to enrollment
- •Known allergy or intolerance to oral vancomycin
- •Unable to comply with the protocol requirements
- •Any condition that in the opinion of the investigator may increase the risk of study participation and/or may interfere with the interpretation of study results
Arms & Interventions
Participants with Immune checkpoint inhibitor-related enterocolitis (irEC)
Experimental
Participants with grade 2-3 diarrhea from irEC who have not yet received immunosuppressive therapy for irEC
Intervention: SER-155 (Biological)
Outcomes
Primary Outcomes
Proportion of patients with treatment-related adverse events
Time Frame: 1 year
Proportion of patients with treatment-related adverse events
Proportion of participants with treatment-related adverse events of special interest
Time Frame: 1 year
Proportion of participants with treatment-related adverse events of special interest, i.e. blood stream infection
Secondary Outcomes
- Proportion of patients with immunosuppressive-free clinical response of irEC (immunotherapy-related enterocolitis) at day 15(Day 15)
- Proportion of patients with immunosuppressive-free clinical remission of irEC at day 15(Day 15)
- Proportion of patients with immunosuppressive-free clinical response of irEC at day 43(Day 43)
- Proportion of patients with immunosuppressive-free clinical remission of irEC at day 43(Day 43)
- Time to immunosuppressive-free clinical response(1 year)
- Time to immunosuppressive-free clinical remission(1 year)
- Number of detectable SER-155 strains at day 15(Day 15)
- Number of detectable SER-155 strains at day 43(Day 43)
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Unknown
Early Phase 1
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT04156269iCell Gene Therapeutics12
Unknown
Early Phase 1
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell MalignanciesB Cell LymphomaB Cell LeukemiaNCT04156178iCell Gene Therapeutics12
Unknown
Early Phase 1
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell MalignanciesB Cell LymphomaB Cell LeukemiaNCT04156243iCell Gene Therapeutics20
Active, not recruiting
Early Phase 1
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MMMultiple MyelomaNCT05302648Hrain Biotechnology Co., Ltd.18
Recruiting
Early Phase 1
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLPlasma Cell LeukemiaMultiple MyelomaNCT06045091Hrain Biotechnology Co., Ltd.18